trial

PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations

NCTId NCT02983058
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 12 (actual)
Sponsored by Jeffrey A. Lieberman, MD
Primary completion 2017-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-11
Primary completion
2017-07
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
pet/spect scanMRI scan

Sponsors

Jeffrey A. Lieberman, MDLead Sponsor

Investigators

1
Sander Markx, MDPrincipal Investigator

Sites

0 total

Facts & assertions

4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2017-07
Status
TERMINATED
relationships
The graph out of here
drug
pet/spect scan
drug
MRI scan
drug
lead_sponsor
Jeffrey A. Lieberman, MD
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Sander Markx, MD
person